LibiGel Worked, the trial was flawed, we will hear soon in my opinion about taking this forward and they will likely partner it out with a big pharma that could do a better trial, as was the case that hgsi had done( finally solved the problem by developing a composite endpoint to minimize the variability.) Hence as this starts to become known, people will run this back over a buck.
AMR bounced from .20 to over a buck after filing for bankruptcy.
BPAX is worth much more then .46 cents, 1.00 near term..
LibiGel actually performed as expected. It raised testosterone levels in the women and increased the number of days with a satisfying sexual event compared with the time before patients were given LibiGel. The problem, as I warned about back in July, stems from the placebo effect, which complicated the results. For instance, in one of the two trials reported yesterday, LibiGel increased the number of satisfying sexual events by 83%, but taking placebo increased it by 65%. The difference wasn't close to being statistically significant; there's a 70% chance that it happened by chance alone.
That's the danger in measuring a subjective outcome; even if the drug works, variability in the outcome can mute the effect. Unfortunately, subjective outcomes can't be avoided for many indications, such as libido or pain management.
The subjective readout for lupus is one of the reasons that there was such a long gap in the development of a treatment. Human Genome Sciences (Nasdaq: HGSI ) finally solved the problem by developing a composite endpoint to minimize the variability.
In terms of trying to boost female sexual desire, investors should have taken a clue from Boehringer Ingelheim, Pfizer (NYSE: PFE ) , and Procter & Gamble (NYSE: PG ) , which all abandoned their female sexual development drugs. Pfizer and Eli Lilly (NYSE: LLY ) had it easier developing drugs for men, where tangible results can be more empirically observed.
News 
Market Data 
Discover 
